Studying the effects of chaperones on amyloid fibril formation

Methods

Volumn 53, Issue 3, 2011, Pages 285-294

  Zhang, Hong ^a   Xu, Li Qiong ^a,b   Perrett, Sarah ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Amyloid; Biosensor assay; Chaperone; Filter retardation assay; Prion; Thioflavin T

Indexed keywords

AMYLOID; CHAPERONE; PRION PROTEIN; THIOFLAVINE;

ALZHEIMER DISEASE; ASSAY; BIOSENSOR; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; FILTER RETARDATION ASSAY; FLUORESCENCE; GEL PERMEATION CHROMATOGRAPHY; LIGHT SCATTERING; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; QUARTZ CRYSTAL MICROBALANCE; REVIEW; SURFACE PLASMON RESONANCE; TEMPERATURE; YEAST;

AMYLOID; CHROMATOGRAPHY, GEL; FILTRATION; FLUOROMETRY; HUMANS; LIGHT; MICROPORE FILTERS; MOLECULAR CHAPERONES; QUARTZ CRYSTAL MICROBALANCE TECHNIQUES; SCATTERING, RADIATION; SURFACE PLASMON RESONANCE; THIAZOLES;

ANIMALIA;

EID: 79952193985     PISSN: 10462023     EISSN: 10959130     Source Type: Journal    
DOI: 10.1016/j.ymeth.2010.11.009     Document Type: Review

References (75)

1. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
2. Perrett S., Jones G.W. Insights into the mechanism of prion propagation. Curr. Opin. Struct. Biol. 2008, 18:52-59.
3. Sipe J.D., Cohen A.S. Review: history of the amyloid fibril. J. Struct. Biol. 2000, 130:88-98.
4. Nilsson M.R. Techniques to study amyloid fibril formation in vitro. Methods 2004, 34:151-160.
5. Jahn T.R., Makin O.S., Morris K.L., Marshall K.E., Tian P., Sikorski P., Serpell L.C. The common architecture of cross-beta amyloid. J. Mol. Biol. 2010, 395:717-727.
6. Jiang Y., Li H., Zhu L., Zhou J.M., Perrett S. Amyloid nucleation and hierarchical assembly of Ure2p fibrils. Role of asparagine/glutamine repeat and nonrepeat regions of the prion domains. J. Biol. Chem. 2004, 279:3361-3369.
7. Hartl F.U., Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002, 295:1852-1858.
8. Glover J.R., Lindquist S. Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins. Cell 1998, 94:73-82.
9. Doyle S.M., Wickner S. Hsp104 and ClpB: protein disaggregating machines. Trends Biochem. Sci. 2009, 34:40-48.
10. Muchowski P.J., Wacker J.L. Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 2005, 6:11-22.
11. Balch W.E., Morimoto R.I., Dillin A., Kelly J.W. Adapting proteostasis for disease intervention. Science 2008, 319:916-919.
12. Jones G.W., Tuite M.F. Chaperoning prions: the cellular machinery for propagating an infectious protein?. Bioessays 2005, 27:823-832.
13. Petkova A.T., Leapman R.D., Guo Z., Yau W.M., Mattson M.P., Tycko R. Self-propagating molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 2005, 307:262-265.
14. Zhu L., Zhang X.J., Wang L.Y., Zhou J.M., Perrett S. Relationship between stability of folding intermediates and amyloid formation for the yeast prion Ure2p: a quantitative analysis of the effects of pH and buffer system. J. Mol. Biol. 2003, 328:235-254.
15. Lopez-Buesa P., Pfund C., Craig E.A. The biochemical properties of the ATPase activity of a 70-kDa heat shock protein (Hsp70) are governed by the C-terminal domains. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:15253-15258.
16. Brange J., Langkjoer L. Insulin structure and stability. Pharm. Biotechnol. 1993, 5:315-350.
17. Fei L., Perrett S. Disulfide bond formation significantly accelerates the assembly of Ure2p fibrils because of the proximity of a potential amyloid stretch. J. Biol. Chem. 2009, 284:11134-11141.
18. Bosl B., Grimminger V., Walter S. Substrate binding to the molecular chaperone Hsp104 and its regulation by nucleotides. J. Biol. Chem. 2005, 280:38170-38176.
19. Gao B., Greene L., Eisenberg E. Characterization of nucleotide-free uncoating ATPase and its binding to ATP, ADP, and ATP analogues. Biochemistry 1994, 33:2048-2054.
20. Doyle S.M., Shorter J., Zolkiewski M., Hoskins J.R., Lindquist S., Wickner S. Asymmetric deceleration of ClpB or Hsp104 ATPase activity unleashes protein-remodeling activity. Nat. Struct. Mol. Biol. 2007, 14:114-122.
21. Frost B., Ollesch J., Wille H., Diamond M.I. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J. Biol. Chem. 2009, 284:3546-3551.
22. Yonetani M., Nonaka T., Masuda M., Inukai Y., Oikawa T., Hisanaga S., Hasegawa M. Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J. Biol. Chem. 2009, 284:7940-7950.
23. Vassar P.S., Culling C.F. Fibrosis of the breast. AMA Arch Pathol 1959, 67:128-133.
24. LeVine H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993, 2:404-410.
25. Eisert R., Felau L., Brown L.R. Methods for enhancing the accuracy and reproducibility of Congo red and thioflavin T assays. Anal. Biochem. 2006, 353:144-146.
26. LeVine H. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999, 309:274-284.
27. Ma X., Liu L., Mao X., Niu L., Deng K., Wu W., Li Y., Yang Y., Wang C. Amyloid beta (1-42) folding multiplicity and single-molecule binding behavior studied with STM. J. Mol. Biol. 2009, 388:894-901.
28. Groenning M. Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils-current status. J. Chem. Biol. 2010, 3:1-18.
29. Chen S., Berthelier V., Hamilton J.B., O'Nuallain B., Wetzel R. Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry 2002, 41:7391-7399.
30. Khurana R., Coleman C., Ionescu-Zanetti C., Carter S.A., Krishna V., Grover R.K., Roy R., Singh S. Mechanism of thioflavin T binding to amyloid fibrils. J. Struct. Biol. 2005, 151:229-238.
31. Sabate R., Saupe S.J. Thioflavin T fluorescence anisotropy: an alternative technique for the study of amyloid aggregation. Biochem. Biophys. Res. Commun. 2007, 360:135-138.
32. Wall J., Murphy C.L., Solomon A. In vitro immunoglobulin light chain fibrillogenesis. Methods Enzymol. 1999, 309:204-217.
33. Lian H.Y., Zhang H., Zhang Z.R., Loovers H.M., Jones G.W., Rowling P.J., Itzhaki L.S., Zhou J.M., Perrett S. Hsp40 interacts directly with the native state of the yeast prion protein Ure2 and inhibits formation of amyloid-like fibrils. J. Biol. Chem. 2007, 282:11931-11940.
34. Zhang H., Loovers H.M., Xu L.Q., Wang M., Rowling P.J., Itzhaki L.S., Gong W., Zhou J.M., Jones G.W., Perrett S. Alcohol oxidase (AOX1) from Pichia pastoris is a novel inhibitor of prion propagation and a potential ATPase. Mol Microbiol 2009, 71:702-716.
35. Huang C., Cheng H., Hao S., Zhou H., Zhang X., Gao J., Sun Q.H., Hu H., Wang C.C. Heat shock protein 70 inhibits alpha-synuclein fibril formation via interactions with diverse intermediates. J. Mol. Biol. 2006, 364:323-336.
36. Davies S.W., Sathasivam K., Hobbs C., Doherty P., Mangiarini L., Scherzinger E., Wanker E.E., Bates G.P. Detection of polyglutamine aggregation in mouse models. Methods Enzymol. 1999, 309:687-701.
37. Scherzinger E., Sittler A., Schweiger K., Heiser V., Lurz R., Hasenbank R., Bates G.P., Lehrach H., Wanker E.E. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:4604-4609.
38. Muchowski P.J., Schaffar G., Sittler A., Wanker E.E., Hayer-Hartl M.K., Hartl F.U. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:7841-7846.
39. Sittler A., Lurz R., Lueder G., Priller J., Lehrach H., Hayer-Hartl M.K., Hartl F.U., Wanker E.E. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 2001, 10:1307-1315.
40. Krol H.A., Krawczyk P.M., Bosch K.S., Aten J.A., Hol E.M., Reits E.A. Polyglutamine expansion accelerates the dynamics of ataxin-1 and does not result in aggregate formation. PLoS One 2008, 3:e1503.
41. Boeddrich A., Lurz R., Wanker E.E. Huntingtin fragments form aggresome-like inclusion bodies in mammalian cells. Methods Mol. Biol. 2003, 232:217-229.
42. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 1999, 38:8972-8980.
43. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:571-656.
44. Dedmon M.M., Christodoulou J., Wilson M.R., Dobson C.M. Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species. J. Biol. Chem. 2005, 280:14733-14740.
45. Murphy R.M., Pallitto M.M. Probing the kinetics of beta-amyloid self-association. J. Struct. Biol. 2000, 130:109-122.
46. Domingues M.M., Santiago P.S., Castanho M.A., Santos N.C. What can light scattering spectroscopy do for membrane-active peptide studies?. J. Pept. Sci. 2008, 14:394-400.
47. Ahmad A., Uversky V.N., Hong D., Fink A.L. Early events in the fibrillation of monomeric insulin. J. Biol. Chem. 2005, 280:42669-42675.
48. Liu R., He M., Su R., Yu Y., Qi W., He Z. Insulin amyloid fibrillation studied by terahertz spectroscopy and other biophysical methods. Biochem. Biophys. Res. Commun. 2010, 391:862-867.
49. Kusumoto Y., Lomakin A., Teplow D.B., Benedek G.B. Temperature dependence of amyloid beta-protein fibrillization. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:12277-12282.
50. Tomski S.J., Murphy R.M. Kinetics of aggregation of synthetic beta-amyloid peptide. Arch. Biochem. Biophys. 1992, 294:630-638.
51. Yagi H., Kusaka E., Hongo K., Mizobata T., Kawata Y. Amyloid fibril formation of alpha-synuclein is accelerated by preformed amyloid seeds of other proteins: implications for the mechanism of transmissible conformational diseases. J. Biol. Chem. 2005, 280:38609-38616.
52. Willander M., Al-Hilli S. Analysis of biomolecules using surface plasmons. Methods Mol. Biol. 2009, 544:201-229.
53. Cooper M.A. Optical biosensors in drug discovery. Nat. Rev. Drug Discov. 2002, 1:515-528.
54. Homola J. Surface plasmon resonance sensors for detection of chemical and biological species. Chem. Rev. 2008, 108:462-493.
55. Homola J. Present and future of surface plasmon resonance biosensors. Anal. Bioanal. Chem. 2003, 377:528-539.
56. Scarano S., Mascini M., Turner A.P., Minunni M. Surface plasmon resonance imaging for affinity-based biosensors. Biosens. Bioelectron. 2010, 25:957-966.
57. Kimple A.J., Muller R.E., Siderovski D.P., Willard F.S. A capture coupling method for the covalent immobilization of hexahistidine tagged proteins for surface plasmon resonance. Methods Mol. Biol. 2010, 627:91-100.
58. Buell A.K., White D.A., Welland M.E., Knowles T.P.J., Dobson C.M. Surface attachment of protein fibrils via covalent modification strategies. J. Phys. Chem. B. 2010, 114:10925-10938.
59. Rich R.L., Myszka D.G. Advances in surface plasmon resonance biosensor analysis. Curr. Opin. Biotechnol. 2000, 11:54-61.
60. Cannon M.J., Williams A.D., Wetzel R., Myszka D.G. Kinetic analysis of beta-amyloid fibril elongation. Anal. Biochem. 2004, 328:67-75.
61. Ryu J., Joung H.A., Kim M.G., Park C.B. Surface plasmon resonance analysis of Alzheimer's beta-amyloid aggregation on a solid surface. from monomers to fully-grown fibrils. Anal. Chem. 2008, 80:2400-2407.
62. White D.A., Buell A.K., Dobson C.M., Welland M.E., Knowles T.P. Biosensor-based label-free assays of amyloid growth. FEBS Lett 2009, 583:2587-2592.
63. Habicht G., Haupt C., Friedrich R.P., Hortschansky P., Sachse C., Meinhardt J., Wieligmann K., Gellermann G.P., Brodhun M., Gotz J., Halbhuber K.J., Rocken C., Horn U., Fandrich M. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:19232-19237.
64. Kawatake S., Nishimura Y., Sakaguchi S., Iwaki T., Doh-ura K. Surface plasmon resonance analysis for the screening of anti-prion compounds. Biol. Pharm. Bull. 2006, 29:927-932.
65. Hou X., Richardson S.J., Aguilar M.I., Small D.H. Binding of amyloidogenic transthyretin to the plasma membrane alters membrane fluidity and induces neurotoxicity. Biochemistry 2005, 44:11618-11627.
66. Lin M.S., Chiu H.M., Fan F.J., Tsai H.T., Wang S.S., Chang Y., Chen W.Y. Kinetics and enthalpy measurements of interaction between beta-amyloid and liposomes by surface plasmon resonance and isothermal titration microcalorimetry. Colloids Surf. B Biointerfaces 2007, 58:231-236.
67. Hou X., Small D.H., Aguilar M.I. Surface plasmon resonance spectroscopy in determination of the interactions between amyloid beta proteins (Abeta) and lipid membranes. Methods Mol. Biol. 2010, 627:225-235.
68. Wilhelmus M.M., Boelens W.C., Otte-Holler I., Kamps B., de Waal R.M., Verbeek M.M. Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity. Brain Res. 2006, 1089:67-78.
69. Knowles T.P., Shu W., Devlin G.L., Meehan S., Auer S., Dobson C.M., Welland M.E. Kinetics and thermodynamics of amyloid formation from direct measurements of fluctuations in fibril mass. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10016-10021.
70. Rodahl M., Hook F., Fredriksson C., Keller C.A., Krozer A., Brzezinski P., Voinova M., Kasemo B. Simultaneous frequency and dissipation factor QCM measurements of biomolecular adsorption and cell adhesion. Faraday Discuss 1997, 229-246.
71. Marx K.A. Quartz crystal microbalance: a useful tool for studying thin polymer films and complex biomolecular systems at the solution-surface interface. Biomacromolecules 2003, 4:1099-1120.
72. Okuno H., Mori K., Okada T., Yokoyama Y., Suzuki H. Development of aggregation inhibitors for amyloid-beta peptides and their evaluation by quartz-crystal microbalance. Chem. Biol. Drug Des. 2007, 69:356-361.
73. White D.A., Buell A.K., Knowles T.P., Welland M.E., Dobson C.M. Protein aggregation in crowded environments. J. Am. Chem. Soc. 2010, 132:5170-5175.
74. Okuno H., Mori K., Jitsukawa T., Inoue H., Chiba S. Convenient method for monitoring Abeta aggregation by quartz-crystal microbalance. Chem. Biol. Drug Des. 2006, 68:273-275.
75. Kotarek J.A., Johnson K.C., Moss M.A. Quartz crystal microbalance analysis of growth kinetics for aggregation intermediates of the amyloid-beta protein. Anal. Biochem. 2008, 378:15-24.